Global Information
회사소개 | 문의
SALE

다발성 경화증(MS) : 시장 인사이트, 역학, 시장 예측(-2027년)

Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027

리서치사 DelveInsight Business Research LLP
발행일 2018년 12월 상품 코드 602106
페이지 정보 영문 100 Pages
가격
US $ 6,250 US $ 5,000 ₩ 5,677,000 PDF by E-mail (Single User License)
US $ 12,500 US $ 8,750 ₩ 9,934,700 PDF by E-mail (Site License)
US $ 18,750 US $ 12,188 ₩ 13,838,200 PDF by E-mail (Global License)


다발성 경화증(MS) : 시장 인사이트, 역학, 시장 예측(-2027년) Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027
발행일 : 2018년 12월 페이지 정보 : 영문 100 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

주요 7개국(미국, 영국, 독일, 프랑스, 이탈리아, 스페인, 일본)의 다발성 경화증(MS: Multiple Sclerosis) 시장을 조사했으며, 시장 및 질병 개요, 아류형·연령대·종합 장애도·성별 유병수 추이와 예측, 국가별 시장 동향, 출시 의약품 및 개발중인 치료제 개요, 시장 성장요인 및 저해요인 분석, 경쟁 구도, 주요 기업 개요 등의 종합적인 정보를 제공합니다.

목차

제1장 중요 통찰

제2장 다발성 경화증(MS) 시장 개요

  • 시장 점유율(실적)
  • 시장 점유율(예측)

제3장 다발성 경화증(MS) : 질환 배경과 개요

  • 서론
  • 증상
  • 아류형
  • 위험인자
  • 원인
  • 병인
  • 진단

제4장 역학과 환자 인구

  • 주요 소견
  • 인구와 예측 파라미터
  • 주요 7개국의 유병수
  • 주요 7개국의 유병수 : 지역별
  • 주요 7개국의 유병수(실적)
  • 주요 7개국의 유병수(예측)

제5장 미국의 다발성 경화증(MS) 시장

  • 미국
    • 유병수
    • 유병수 : 성별
    • 유병수 : 아류형
    • 유병수 : 연령별
    • 유병수 : 종합 장애도(EDSS)별

제6장 EU 5개국의 다발성 경화증(MS) 시장

  • 독일
    • 유병수
    • 유병수 : 성별
    • 유병수 : 아류형
    • 유병수 : 연령별
    • 유병수 : 종합 장애도(EDSS)별
  • 프랑스
    • 유병수
    • 유병수 : 성별
    • 유병수 : 아류형
    • 유병수 : 연령별
    • 유병수 : 종합 장애도(EDSS)별
  • 이탈리아
    • 유병수
    • 유병수 : 성별
    • 유병수 : 아류형
    • 유병수 : 연령별
    • 유병수 : 종합 장애도(EDSS)별
  • 스페인
    • 유병수
    • 유병수 : 성별
    • 유병수 : 아류형
    • 유병수 : 연령별
    • 유병수 : 종합 장애도(EDSS)별
  • 영국
    • 유병수
    • 유병수 : 성별
    • 유병수 : 아류형
    • 유병수 : 연령별
    • 유병수 : 종합 장애도(EDSS)별

제7장 일본의 다발성 경화증(MS) 시장

  • 유병수
  • 유병수 : 성별
  • 유병수 : 아류형
  • 유병수 : 연령별
  • 유병수 : 종합 장애도(EDSS)별

제8장 치료

  • 영국 신경학회 : 다발성 경화증(MS) 개정 가이드라인

제9장 미충족 요구

제10장 출시된 치료제

  • Betaferon : Bayer Healthcare
    • 의약품 개요
    • 작용기전
    • 규제 마일스톤
    • 장단점
    • 안전성과 유효성
    • 제품 개요
  • Rebif : Merck KGA
  • Copaxone : Teva Pharmaceutical
  • Avonex : Biogen Idec. Limited
  • Tysabri : Biogen Idec. Limited
  • Fampyra/Ampyra : Acorda Therapeutics/ Biogen Idec Ltd.
  • Gilenya : Novartis
  • Aubagio : Genzyme
  • Tecfidera : Biogen Idec Ltd.
  • Plegridy : Biogen Idec Ltd.
  • Lemtrada : Genzyme
  • Zinbryta : Biogen Idec
  • Ocrevus : Genentech
  • Mavenclad : Merck

제11장 신약

  • 주요 교차 경쟁
  • III상 임상시험 중인 의약품
    • ALKS 8700 : Biogen
    • Ublituximab : TG Therapeutics
    • Ozanimod : Celgene Corporation
    • OMB157 : Novartis
    • MD1003 : MedDay Pharma
    • Masitinib : AB Science
    • Siponimod : Novartis
    • Ponesimod : Johnson & Johnson
    • Evobrutinib : Merck
    • ADS-5102 : Adamas Pharmaceuticals

제12장 주요 7개국 시장 분석

  • 주요 소견

제13장 시장 규모 추이와 예측 : 국가별

  • 시장 규모 : 치료제별
  • 시장 점유율 : 투여 경로별
  • 시장 점유율 : 투여 경로별

제14장 미국 시장 전망

  • 시장 규모 : 치료제별

제15장 EU 5개국 시장 전망

  • 시장 규모 : 치료제별

제16장 일본 시장 전망

  • 시장 규모 : 치료제별

제17장 비용 분석

제18장 경쟁 구도

제19장 시장 성장 촉진요인

제20장 시장 성장 저해요인

제21장 부록

  • 조사 방법

제22장 DelveInsight의 서비스 내용

제23장 면책사항

제24장 DelveInsight에 대해

LSH 18.04.09

List of Tables

  • Table 1: Characteristics of MS Subtypes
  • Table 2: The 2010 revised McDonald criteria for diagnosis of MS
  • Table 3: Total Prevalent Population of Multiple Sclerosis (MS) in 7 MM (2016-2027)
  • Table 4: Prevalent Population of Multiple Sclerosis (MS) in 7MM- By Region (2016-2027)
  • Table 5: Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 6: Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 7: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 8: Age Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Table 9: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in United States (2016-2027)
  • Table 10: Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 11: Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 12: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 13: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Table 14: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Germany (2016-2027)
  • Table 15: Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 16: Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 17: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 18: Age Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Table 19: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in France (2016-2027)
  • Table 20: Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 21:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 22:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 23:Age Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Table 24: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Italy (2016-2027)
  • Table 25:Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 26:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 27:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 28:Age Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Table 29:Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Spain (2016-2027)
  • Table 30:Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 31:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 32:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 33:Age Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Table 34:Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in United Kingdom (2016-2027)
  • Table 35:Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 36:Sex-Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 37:Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 38:Age Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Table 39: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Japan (2016-2027)
  • Table 40:Medications for the treatment of MS
  • Table 41: Comparison of emerging drugs (Immunomodulators) under development
  • Table 42: Comparison of emerging drugs (other classes) under development
  • Table 43: ALKS 8700 Clinical Trial Description, 2018
  • Table 44: Ublituximab, Clinical Trial Description, 2018
  • Table 45: RPC1063, Clinical Trial Description, 2018
  • Table 46: Ofatumumab, Clinical Trial Description, 2018
  • Table 47: MD1003, Clinical Trial Description, 2018
  • Table 48: Masitinib, Clinical Trial Description, 2018
  • Table 49: BAF312, Clinical Trial Description, 2018
  • Table 50: Ponesimod, Clinical Trial Description, 2018
  • Table 51: Evobrutinib, Clinical Trial Description, 2018
  • Table 52: ADS-5102, Clinical Trial Description, 2018
  • Table 53: Global Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 54: Global Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Table 55: Global Market Share of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2027)
  • Table 56: Global Market Size of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2027)
  • Table 57: Global Market share of Multiple Sclerosis (MS) (MS) therapies by RoA in USD, Million (2016 & 2027)
  • Table 58: Global Market size of Multiple Sclerosis (MS) (MS) therapies by RoA in USD, Million (2016 & 2027)
  • Table 59: The US Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 60: The US Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Table 61: EU5 Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 62: EU5 Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Table 63: Germany Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 64: France Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 65: Italy Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 66: UK Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 67: UK Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 68: Japan Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Table 69:Japan Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)

List of Figures

  • Figure 1: Types of Multiple Sclerosis (MS)
  • Figure 2: Risk factors for Multiple Sclerosis (MS)
  • Figure 3: The immunological complexity of the immune/cytokine network in Multiple Sclerosis (MS)
  • Figure 4: Total Prevalent Population of Multiple Sclerosis (MS) in 7 MM (2016-2027)
  • Figure 5: Prevalent Population of Multiple Sclerosis (MS) in 7MM- By Region (2016-2027)
  • Figure 6: Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 7: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 8: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 9: Age Specific Prevalent Population of Multiple Sclerosis (MS) in United States (2016-2027)
  • Figure 10: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in US (2016-2027)
  • Figure 11: Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 12: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 13: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 14: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Germany (2016-2027)
  • Figure 15: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Germany (2016-2027)
  • Figure 16: Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 17: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 18: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 19: Age Specific Prevalent Population of Multiple Sclerosis (MS) in France (2016-2027)
  • Figure 20: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in France (2016-2027)
  • Figure 21: Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 22: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 23: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 24: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Italy (2016-2027)
  • Figure 25: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Italy (2016-2027)
  • Figure 26: Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 27: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 28: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 29: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Spain (2016-2027)
  • Figure 30: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Spain (2016-2027)
  • Figure 31: Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 32: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 33: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 34: Age Specific Prevalent Population of Multiple Sclerosis (MS) in United Kingdom (2016-2027)
  • Figure 35: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in UK (2016-2027)
  • Figure 36: Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 37: Sex- Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 38: Sub-type Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 39: Age Specific Prevalent Population of Multiple Sclerosis (MS) in Japan (2016-2027)
  • Figure 40: Prevalent Population of Multiple Sclerosis (MS) based on EDSS Score in Japan (2016-2027)
  • Figure 41: Treatment algorithm for Multiple Sclerosis (MS)
  • Figure 42: Diagnosis and Therapy selection
  • Figure 43: Unmet Needs of Multiple Sclerosis (MS) Disease
  • Figure 44: Global Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Figure 45: Global Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027
  • Figure 46: Global Market Share of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2027)
  • Figure 47: Global Market Size of Multiple Sclerosis (MS) (MS) by Line of Therapies in USD, Million (2016 & 2025)
  • Figure 48: Global Market share of Multiple Sclerosis (MS) (MS) therapies by RoA (2016 & 2027)
  • Figure 49: Global Market size of Multiple Sclerosis (MS) (MS) therapies by RoA in USD, Million (2016 & 2027)
  • Figure 50: The US Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Figure 51: The US Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2016-2027)
  • Figure 52: EU5 Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2016-2027)
  • Figure 53: EU5 Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2015-2025)
  • Figure 54: Germany Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 55: France Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 56: Italy Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 57: Spain Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 58: UK Market Size of Multiple Sclerosis (MS) in USD, Million (2015-2025)
  • Figure 59: Japan Market Size of Multiple Sclerosis (MS) (MS) in USD, Million (2015-2025)
  • Figure 60: Japan Market Size of Multiple Sclerosis (MS) (MS) by Therapies in USD, Million (2015-2025)
  • Figure 61: Market Drivers
  • Figure 62:Market Barriers

DelveInsight's Multiple Sclerosis (MS) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical &forecasted epidemiology as well as the market trends of Multiple Sclerosis (MS) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Multiple Sclerosis (MS) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Multiple Sclerosis (MS) Disease Understanding and Treatment Algorithm

Multiple Sclerosis (MS) is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis (MS), body's own immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin which is responsible for protecting the nerve fibers. This is often characterized by relapsing episodes of neurologic impairment followed by remissions.

There are four major categories in Multiple Sclerosis (MS). These are: Relapsing-Remitting Multiple Sclerosis, Secondary-Progressive Multiple Sclerosis, Primary-Progressive Multiple Sclerosis, and Progressive-Relapsing Multiple Sclerosis.

Multiple Sclerosis (MS) individuals may experience a variety of symptoms, physically, emotionally, mentally and psychologically. The severity and types of symptoms differ among the individuals; thus symptoms differ among different people.

The DelveInsight Multiple Sclerosis (MS) market report gives the thorough understanding of the MS by including details such as disease definition, types, symptoms, risk factors, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Multiple Sclerosis (MS) in the US, Europe, and Japan.

Multiple Sclerosis (MS) Epidemiology:

The Multiple Sclerosis (MS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Population of Multiple Sclerosis (MS), Sex-Specific Prevalence of Multiple Sclerosis (MS), Sub-type Specific Prevalence of Multiple Sclerosis (MS), Age-Specific Prevalence of Multiple Sclerosis (MS) and Prevalence of Multiple Sclerosis (MS) based on EDSS Score] scenario of Multiple Sclerosis (MS) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom), and Japan from 2016-2027.

According to DelveInsight, total prevalent population of Multiple Sclerosis (MS) in 7 major markets is estimated approximately 1,980,782 in 2016 and it is expected to be increase in forecasted period 2016-2027. It is also estimated that, with the higher prevalence of Multiple Sclerosis (MS) in United States with 1,301,558 prevalent population in 2016 will also increase in 2027.

Multiple Sclerosis (MS) Drug Chapters:

This segment of the Multiple Sclerosis (MS) report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, there are some FDA approved therapies for the treatment of Multiple Sclerosis (MS) include-Betaferon (Bayer Healthcare), Rebif (Merck KGA), Copaxone (Teva Pharmaceutical), Avonex (Biogen), Tysabri (Biogen), Fampyra/Ampyra (Acorda Therapeutics/ Biogen), Gilenya (Novartis), Aubagio (Genzyme), Tecfidera (Biogen), Plegridy (Biogen), Lemtrada (Genzyme), Zinbryta (Biogen) , Ocrevus (Genentech), Mavenclad (Merck).

Apart from all these approved products, there are few promising candidates in the pivotal stage of clinical development, which are expected to boom the market size of Multiple Sclerosis (MS) during our forecast period (2018-2027). These emerging drugs mainly include Siponimod (BAF312; Novartis), Ponesimod (ACT-128800; Johnson and Johnson), Ozanimod (RPC1063; Celgene), Ofatumumab (Novartis), Ublituximab (TG Therapeutics), ALKS 8700 (Alkermes Plc), Gocovri (Adamas Pharmaceuticals), Evobrutinib (Merck KgaA) and Mavenclad (Merck KgaA).

Multiple Sclerosis (MS) Market Outlook:

The Multiple Sclerosis (MS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Multiple Sclerosis (MS) in 7MM was found to be USD 21,248 million in 2016, and is expected to increase in 2027.

According to DelveInsight, the United States accounts for the largest market size of Multiple Sclerosis (MS), in comparison to the other 7 MM countries i.e., EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

Multiple Sclerosis (MS) Drugs Uptake:

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Multiple Sclerosis (MS) Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Multiple Sclerosis (MS) Report Key Strengths:

  • 10 Years Forecast
  • 7MMCoverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Multiple Sclerosis (MS) Report Assessment:

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits:

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Multiple Sclerosis (MS) market
  • Organize sales and marketing efforts by identifying the best opportunities for Multiple Sclerosis (MS) (MS) market
  • To understand the future market competition in the Multiple Sclerosis (MS) market.

Note: We understand the needs of the rapidly changing market and DelveInsight's is helping the client by providing the most up to date Report.

Table of Contents

1. Key Insights

2. Multiple Sclerosis (MS) Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Multiple Sclerosis (MS) in 2016
  • 2.2. Market Share (%) Distribution of Multiple Sclerosis (MS) in 2027

3. Multiple Sclerosis (MS): Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Symptoms
  • 3.3. Types of Multiple Sclerosis (MS)
  • 3.4. Risk Factors
  • 3.5. Causes
  • 3.6. Pathogenesis
  • 3.7. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. 7MM Total Prevalent Population of Multiple Sclerosis (MS)
  • 4.4. Prevalent Population of Multiple Sclerosis (MS) in 7MM - By Region
  • 4.5. Prevalent Population of Multiple Sclerosis (MS) in 7MM - Distribution (2016)
  • 4.6. Prevalent Population of Multiple Sclerosis (MS) in 7MM - Distribution (2027)

5. Country Wise-Epidemiology of Multiple Sclerosis (MS)

  • 5.1. United States
    • 5.1.1. Prevalent Population of Multiple Sclerosis (MS) in the United States
    • 5.1.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in the United States
    • 5.1.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in the United States
    • 5.1.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in the United States
    • 5.1.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in the United States

6. EU5 Countries

  • 6.1. Germany
    • 6.1.1. Prevalent Population of Multiple Sclerosis (MS) in Germany
    • 6.1.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Germany
    • 6.1.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Germany
    • 6.1.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in Germany
    • 6.1.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Germany
  • 6.2. France
    • 6.2.1. Prevalent Population of Multiple Sclerosis (MS) in France
    • 6.2.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.2.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.2.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.2.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in France
  • 6.3. Italy
    • 6.3.1. Prevalent Population of Multiple Sclerosis (MS) in Italy
    • 6.3.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Italy
    • 6.3.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Italy
    • 6.3.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in Italy
    • 6.3.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Italy
  • 6.4. Spain
    • 6.4.1. Prevalent Population of Multiple Sclerosis (MS) in Spain
    • 6.4.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Spain
    • 6.4.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Spain
    • 6.4.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in France
    • 6.4.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Spain
  • 6.5. United Kingdom
    • 6.5.1. Prevalent Population of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in United Kingdom
    • 6.5.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in United Kingdom

7. Japan

  • 7.1. Prevalent Population of Multiple Sclerosis (MS) in Japan
  • 7.2. Sex-Specific Prevalence of Multiple Sclerosis (MS) in Japan
  • 7.3. Sub-type Specific Prevalence of Multiple Sclerosis (MS) in Japan
  • 7.4. Age-Specific Prevalence of Multiple Sclerosis (MS) in Japan
  • 7.5. Prevalence of Multiple Sclerosis (MS) based on EDSS Score in Japan

8. Treatment

  • 8.1. Association of British Neurologists: Revised Guidelines for prescribing disease-modifying treatments in Multiple Sclerosis (MS) (2016)
  • 8.2. Overcoming barriers in Progressive Multiple Sclerosis (MS) treatment

9. Unmet Needs

10. Marketed Drugs

  • 10.1. Betaferon: Bayer Healthcare
    • 10.1.1. Drug Description
    • 10.1.2. Mechanism of Action
    • 10.1.3. Regulatory Milestones
    • 10.1.4. Advantages & Disadvantages
    • 10.1.5. Safety and Efficacy
    • 10.1.6. Product Profile
  • 10.2. Rebif: Merck KGA
    • 10.2.1. Drug Description
    • 10.2.2. Mechanism of Action
    • 10.2.3. Regulatory Milestones
    • 10.2.4. Advantages & Disadvantages
    • 10.2.5. Safety and Efficacy
    • 10.2.6. Product Profile
  • 10.3. Copaxone: Teva Pharmaceutical
    • 10.3.1. Drug Description
    • 10.3.2. Mechanism of action
    • 10.3.3. Regulatory Milestones
    • 10.3.4. Advantages & Disadvantages
    • 10.3.5. Safety and Efficacy
    • 10.3.6. Product Profile
  • 10.4. Avonex: Biogen Idec. Limited
    • 10.4.1. Drug Description
    • 10.4.2. Mechanism of action
    • 10.4.3. Regulatory Milestones
    • 10.4.4. Advantages & Disadvantages
    • 10.4.5. Safety and efficacy
    • 10.4.6. Product Profile
  • 10.5. Tysabri: Biogen Idec. Limited
    • 10.5.1. Drug Description
    • 10.5.2. Mechanism of action
    • 10.5.3. Regulatory Milestones
    • 10.5.4. Advantages & Disadvantages
    • 10.5.5. Safety and efficacy of Tysabri
    • 10.5.6. Product Profile
  • 10.6. Fampyra/Ampyra: Acorda Therapeutics/ Biogen Idec Ltd.
    • 10.6.1. Drug Description
    • 10.6.2. Mechanism of action
    • 10.6.3. Regulatory Milestones
    • 10.6.4. Advantages & Disadvantages
    • 10.6.5. Safety and efficacy
    • 10.6.6. Product Profile
  • 10.7. Gilenya: Novartis
    • 10.7.1. Drug Description
    • 10.7.2. Mechanism of action
    • 10.7.3. Regulatory Milestones
    • 10.7.4. Advantages & Disadvantages
    • 10.7.5. Safety and efficacy of Gilenya
    • 10.7.6. Product Profile
  • 10.8. Aubagio: Genzyme
    • 10.8.1. Drug Description
    • 10.8.2. Mechanism of action
    • 10.8.3. Regulatory Milestones
    • 10.8.4. Advantages & Disadvantages
    • 10.8.5. Safety and efficacy
    • 10.8.6. Product Profile
  • 10.9. Tecfidera: Biogen Idec Ltd.
    • 10.9.1. Drug Description
    • 10.9.2. Mechanism of action
    • 10.9.3. Regulatory Milestones
    • 10.9.4. Advantages & Disadvantages
    • 10.9.5. Safety and efficacy
    • 10.9.6. Product Profile
  • 10.10. Plegridy: Biogen Idec Ltd.
    • 10.10.1. Drug Description
    • 10.10.2. Mechanism of action
    • 10.10.3. Regulatory Milestones
    • 10.10.4. Advantages & Disadvantages
    • 10.10.5. Safety and efficacy
    • 10.10.6. Product Profile
  • 10.11. Lemtrada: Genzyme
    • 10.11.1. Drug Description
    • 10.11.2. Mechanism of action
    • 10.11.3. Regulatory Milestones
    • 10.11.4. Advantages & Disadvantages
    • 10.11.5. Safety and efficacy
    • 10.11.6. Product Profile
  • 10.12. Zinbryta: Biogen Idec
    • 10.12.1. Drug Description
    • 10.12.2. Mechanism of action
    • 10.12.3. Regulatory Milestones
    • 10.12.4. Advantages & Disadvantages
    • 10.12.5. Safety and efficacy
    • 10.12.6. Product Profile
  • 10.13. Ocrevus: Genentech
    • 10.13.1. Drug Description
    • 10.13.2. Mechanism of action
    • 10.13.3. Regulatory Milestones
    • 10.13.4. Advantages & Disadvantages
    • 10.13.5. Safety and efficacy
    • 10.13.6. Product Profile
  • 10.14. Mavenclad: Merck
    • 10.14.1. Drug Description
    • 10.14.2. Mechanism of action
    • 10.14.3. Regulatory Milestones
    • 10.14.4. Safety and efficacy
    • 10.14.5. Advantages & Disadvantages
    • 10.14.6. Product Profile

11. Emerging Drugs

  • 11.1. Key Cross Competition
  • 11.2. Phase III Drugs
    • 11.2.1. ALKS 8700: Biogen
      • 11.2.1.1. Other development activities
      • 11.2.1.2. Clinical Development
      • 11.2.1.3. Clinical Trials Information
      • 11.2.1.4. Safety and Efficacy
      • 11.2.1.5. Advantages and Disadvantages
      • 11.2.1.6. Product Profile
    • 11.2.2. Ublituximab: TG Therapeutics
      • 11.2.2.1. Other development activities
      • 11.2.2.2. Clinical Development
      • 11.2.2.3. Clinical Trials Information
      • 11.2.2.4. Safety and Efficacy
      • 11.2.2.5. Advantages and Disadvantages
      • 11.2.2.6. Product Profile
    • 11.2.3. Ozanimod: Celgene Corporation
      • 11.2.3.1. Other development activities
      • 11.2.3.2. Clinical Development
      • 11.2.3.3. Clinical Trials Information
      • 11.2.3.4. Safety and Efficacy
      • 11.2.3.5. Advantages and Disadvantages
      • 11.2.3.6. Product Profile
    • 11.2.4. OMB157: Novartis
      • 11.2.4.1. Other development activities
      • 11.2.4.2. Clinical Development
      • 11.2.4.3. Clinical Trials Information
      • 11.2.4.4. Safety and Efficacy
      • 11.2.4.5. Advantages and Disadvantages
      • 11.2.4.6. Product Profile
    • 11.2.5. MD1003: MedDay Pharma
      • 11.2.5.1. Other development activities
      • 11.2.5.2. Clinical Development
      • 11.2.5.3. Clinical Trials Information
      • 11.2.5.4. Safety and Efficacy
      • 11.2.5.5. Advantages and Disadvantages
      • 11.2.5.6. Product Profile
    • 11.2.6. Masitinib: AB Science
      • 11.2.6.1. Other regulatory milestone
      • 11.2.6.2. Clinical Development
      • 11.2.6.3. Clinical Trials Information
      • 11.2.6.4. Safety and Efficacy
      • 11.2.6.5. Advantages and Disadvantages
      • 11.2.6.6. Product Profile
    • 11.2.7. Siponimod: Novartis
      • 11.2.7.1. Other development activities
      • 11.2.7.2. Clinical Development
      • 11.2.7.3. Clinical Trials Description
      • 11.2.7.4. Safety and Efficacy
      • 11.2.7.5. Advantages and Disadvantages
      • 11.2.7.6. Product Profile
    • 11.2.8. Ponesimod: Johnson & Johnson
      • 11.2.8.1. Other regulatory milestones
      • 11.2.8.2. Clinical Development
      • 11.2.8.3. Clinical Trials Description
      • 11.2.8.4. Safety and Efficacy
      • 11.2.8.5. Advantages and Disadvantages
      • 11.2.8.6. Product Profile
    • 11.2.9. Evobrutinib: Merck
      • 11.2.9.1. Product Description
      • 11.2.9.2. Other Developmental Activities
      • 11.2.9.3. Clinical Development
      • 11.2.9.4. Safety and Efficacy
      • 11.2.9.5. Product Profile
    • 11.2.10. ADS-5102: Adamas Pharmaceuticals
      • 11.2.10.1. Product Description
      • 11.2.10.2. Other Developmental Activities
      • 11.2.10.3. Clinical Development
      • 11.2.10.4. Safety and Efficacy
      • 11.2.10.5. Product Profile

12. Multiple Sclerosis (MS): 7 Major Market Analysis

  • 12.1. Key Findings

13. Global Market Size by Therapies

  • 13.1. Global Market Size by Line of Therapies
  • 13.2. Global Market Share of Therapies by Route of Administration (RoA)
  • 13.3. Global Market Size by Route of Administration (RoA)

14. The United States Market Outlook

  • 14.1. Market Size by Therapies

15. EU-5 Countries: Market Outlook

  • 15.1. Market Size of MS by Therapies in EU5

16. Japan-MS Market Size

17. Cost Analysis of Multiple Sclerosis (MS)

18. Generic Competition in MS Market

19. Market Drivers

20. Market Barriers

21. Appendix

  • 21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Back to Top
전화 문의
이용안내
 
BCC Research